Clinical trials: Chronic Leukaemia
Chronic Phase Chronic Myeloid Leukemia
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
The purpose of this study is to compare the efficacy and safety of 2 starting doses of ponatinib compared to nilotinib in participants with imatinib-resistant chronic myeloid leukemia (CML) in chronic phase (CP).
- Trial name
- OPTIC-2L (NCT02627677)
- Testing
- Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- Ariad Pharmaceuticals
Leukaemia, Lymphocytic, Chronic
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
Ofatumumab is an IgG1κ fully human monoclonal antibody (mAb) that specifically recognizes an epitope on the human differentiation antigen CD20 molecule.
- Trial name
- NCT01077622
- Testing
- ofatumumab 100 mg, 1000 mg / vial
- Where
- 7 sites in Japan, South Korea
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor.
- Conditions
- Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT04279405
- Testing
- YY-20394
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Leukemia
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00086775
- Testing
- alemtuzumab, rituximab, fludarabine phosphate
- Where
- 5 sites in United States
- Sponsor
- Bayer
Healthy
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
A first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of ZE50-0134 administered orally in healthy volunteers.
- Trial name
- NCT06787131
- Testing
- Rabeprazole 20 mg, Itraconazole (200 mg)
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Leukemia
Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
RATIONALE: Drugs used in chemotherapy, such as everolimus, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00093639
- Testing
- everolimus, imatinib mesylate
- Where
- United States
- Sponsor
- Novartis Pharmaceuticals
B Cell Chronic Lymphocytic Leukemia
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
This is a Phase III, open-label, multicenter, randomized, comparative study of Campath versus chlorambucil as front line therapy in patients with progressive B-Cell Lymphocytic Leukemia (B-CLL).
- Trial name
- NCT00046683
- Testing
- alemtuzumab
- Where
- 20 sites in United States
- Volunteers
- 284 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia (CMML)
SNS-301 Monotherapy in High Risk MDS and CMML
To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 in patients with ASPH+ high risk MDS and CMML.
- Trial name
- NCT04217720
- Testing
- SNS-301
- Sponsor
- Sensei Biotherapeutics, Inc.
Leukemia
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may help fludarabine and cyclophosphamide kill more cancer cells by making them more sensitive to…
- Trial name
- NCT00024440
- Testing
- filgrastim, oblimersen sodium, cyclophosphamide
- Where
- United States
- Sponsor
- Genta Incorporated
Leukaemia, Lymphocytic, Chronic
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects
Ofatumumab is a fully-human monoclonal antibody that exhibits high binding affinity to an antigen on the surface of B lymphocytes.
- Trial name
- NCT01110031
- Testing
- Ofatumumab
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
CLL/SLL
Global Trial in APG2575 for Patients With CLL/SLL
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK…
- Trial name
- NCT06104566
- Testing
- lisaftoclax +BTK inhibitor, BTK inhibitor
- Where
- 135 sites in United States, Australia and 17 more
- Volunteers
- 400 people
- Sponsor
- Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL.
- Trial name
- LUCID (NCT00391066)
- Testing
- FCR + Lumiliximab, FCR
- Where
- 194 sites in United States, Argentina and 21 more
- Volunteers
- 627 people
- Sponsor
- Biogen
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
This study will assess the efficacy, safety and pharmacodynamic markers of the study drug, A6, in patients with CLL and small lymphocytic lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL, SLL
- Trial name
- NCT02046928
- Testing
- A6
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ångstrom Pharmaceuticals
Chronic Lymphocytic Leukemia
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to see at what dose MDX-1342, a monoclonal antibody, is safe and tolerable for patients with chronic lymphocytic leukemia (CLL).
- Trial name
- MDX1342-02 (NCT00593944)
- Testing
- MDX-1342
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory…
- Trial name
- NCT03922100
- Testing
- NMS-03592088
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 63 people
- Sponsor
- Nerviano Medical Sciences
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a…
- Trial name
- NCT07221500
- Testing
- NX-5948
- Where
- 43 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Nurix Therapeutics, Inc.
Chronic Lymphocytic Leukemia
A Phase I/II Study of GX15-070MS in Untreated CLL
This protocol is being run to determine the best phase II dose and schedule of obatoclax in patients with previously untreated CLL.
- Trial name
- NCT00600964
- Testing
- GX15-070MS
- Where
- 5 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Gemin X
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with advanced tumors unresponsive to standard…
- Conditions
- Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma
- Trial name
- NCT01353625
- Testing
- CC-115
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 118 people
- Sponsor
- Celgene